Diagnostic Test: A New Step Forward
Unlocking Long COVID: Genetic Clues Emerge in Landmark Genome-Wide Study
A groundbreaking genome-wide association study (GWAS) has identified specific genetic variants within the FOXP4 gene that are significantly linked to an increased risk of developing long COVID. the research, published in Nature Genetics, analyzed the genetic data of over 1.9 million individuals, providing crucial insights into the biological mechanisms underlying this complex post-viral condition.
The study found that genetic variations in FOXP4, a gene known to influence lung function, were statistically associated with a higher risk of long COVID. Notably,individuals with long COVID exhibited higher expression levels of the FOXP4 gene compared to control groups. crucially, the identified risk variants demonstrated a consistent effect across diverse ancestries, underscoring their broad relevance.
Beyond genetic predispositions, the research also confirmed a causal relationship between SARS-CoV-2 infection and the development of long COVID. Furthermore, infections severe enough to necessitate hospitalization were found to carry an additional causal risk for the condition. The study also explored potential links between long COVID-associated variants and those implicated in other diseases, hinting at shared biological pathways.
These findings align with existing research suggesting that both individual genetic factors and environmental influences contribute to long COVID risk. The authors concluded that the study provides genetic evidence connecting abnormal lung physiology to the development of long COVID, while acknowledging that long COVID symptoms extend beyond respiratory issues to include fatigue and cognitive dysfunction.
Hanna Ollila, PhD, a co-author of the study from the institute for Molecular Medicine Finland and Massachusetts General Hospital, emphasized that the newly identified genetic variants are not currently predictive for individual clinical tests or personal disease risk.
“The findings from our study, and from genome-wide association studies in general, tell about biological mechanisms behind a disease,” explained Ollila. “This can then help to understand the disease better. For exmaple, is it a disease neuronal, immune, metabolic, and so on?” She further clarified that while these discoveries illuminate biological pathways, the journey to developing diagnostic tests is lengthy, as these genetic variants do not function as high-impact predictors like BRCA mutations in breast cancer.
“In other words, they do not strongly predict whether someone will develop long COVID at the individual level,” ollila stated. “Rather, they highlight the biological systems involved in the disease. In this case,our findings point to immune pathways related to lung function.”
ollila elaborated that genetics can guide diagnostic development by pinpointing underlying mechanisms, which may subsequently lead to the identification of biomarkers in blood or other tissues. These biomarkers could eventually contribute to diagnostic tools, but this process requires time, collaboration, and advancements across multiple research fields, including imaging and clinical phenotyping.
Researchers anticipate that as larger sample sizes become available for future studies, the precision of analyses and understanding of correlations will improve, offering greater clarity on genetic risk factors, biological mechanisms, and potential biomarkers for long COVID diagnosis.”We are likely still several years away, and possibly even a decade or more, from having a clinically useful diagnostic test based on genetic or biological markers for long COVID,” Ollila commented.”That said, progress is accelerating thanks to the growing number of well-characterized cohorts and international collaborations. While these genetic findings are not yet ready for clinical application, they are an important step toward understanding long COVID, its relationship with other diseases, and the disease mechanisms that modulate risk for long COVID.”